MX2023001461A - Composiciones para la administracion de moleculas de carga activa al epitelio de las vias respiratorias. - Google Patents
Composiciones para la administracion de moleculas de carga activa al epitelio de las vias respiratorias.Info
- Publication number
- MX2023001461A MX2023001461A MX2023001461A MX2023001461A MX2023001461A MX 2023001461 A MX2023001461 A MX 2023001461A MX 2023001461 A MX2023001461 A MX 2023001461A MX 2023001461 A MX2023001461 A MX 2023001461A MX 2023001461 A MX2023001461 A MX 2023001461A
- Authority
- MX
- Mexico
- Prior art keywords
- epithelium
- administration
- compositions
- respiratory tract
- active charge
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062367P | 2020-08-06 | 2020-08-06 | |
| PCT/US2021/045038 WO2022032154A2 (en) | 2020-08-06 | 2021-08-06 | Compositions for the delivery of payload molecules to airway epithelium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001461A true MX2023001461A (es) | 2023-04-26 |
Family
ID=77543659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001461A MX2023001461A (es) | 2020-08-06 | 2021-08-06 | Composiciones para la administracion de moleculas de carga activa al epitelio de las vias respiratorias. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230285310A1 (https=) |
| EP (1) | EP4192433A2 (https=) |
| JP (1) | JP2023538260A (https=) |
| KR (1) | KR20230087443A (https=) |
| CN (1) | CN116348147A (https=) |
| AU (1) | AU2021320426A1 (https=) |
| BR (1) | BR112023001955A2 (https=) |
| CA (1) | CA3189854A1 (https=) |
| IL (1) | IL300111A (https=) |
| MA (1) | MA71659A (https=) |
| MX (1) | MX2023001461A (https=) |
| TW (1) | TW202214215A (https=) |
| WO (1) | WO2022032154A2 (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
| AU2016341309A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| EP3668979A4 (en) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | METHOD OF HPLC ANALYSIS |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| HRP20240586T1 (hr) | 2018-10-09 | 2024-07-19 | The University Of British Columbia | Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| EP4274607A1 (en) | 2021-01-11 | 2023-11-15 | ModernaTX, Inc. | Seasonal rna influenza virus vaccines |
| JP2024511463A (ja) | 2021-03-22 | 2024-03-13 | リコード セラピューティクス，インク． | 細胞への標的送達のための組成物および方法 |
| CA3213107A1 (en) | 2021-03-23 | 2022-09-29 | Mirko HENNIG | Polynucleotide compositions, related formulations, and methods of use thereof |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| WO2023076598A1 (en) * | 2021-10-29 | 2023-05-04 | Modernatx, Inc. | Lipid amines |
| US20250281419A1 (en) * | 2021-10-29 | 2025-09-11 | Modernatx, Inc. | Lipid amines |
| CN118829423A (zh) * | 2021-11-12 | 2024-10-22 | 摩登纳特斯有限公司 | 用于将有效载荷分子递送至气道上皮的组合物 |
| EP4475882A1 (en) | 2022-02-09 | 2024-12-18 | ModernaTX, Inc. | Mucosal administration methods and formulations |
| EP4479082A2 (en) * | 2022-02-15 | 2024-12-25 | The Broad Institute, Inc. | Cell-type specific targeting contractile injection system |
| US20250188028A1 (en) * | 2022-03-14 | 2025-06-12 | Nanovation Therapeutics Inc. | Synthetic Method for Producing Ionizable Amino Lipids |
| EP4509544A4 (en) * | 2022-04-12 | 2025-07-02 | Xiamen Sinopeg Biotech Co Ltd | NONLINEAR PEGYLATED LIPID CONTAINING TERTIARY AMINE AND ITS APPLICATION |
| CN117003808A (zh) * | 2022-04-28 | 2023-11-07 | 北京科兴中维生物技术有限公司 | 一种阳离子脂质化合物及其制备方法和用途 |
| CN119816292A (zh) * | 2022-08-08 | 2025-04-11 | 先进核糖核酸疫苗(Arv)技术股份有限公司 | 基于甾醇的可电离脂质以及包含其的脂质纳米颗粒 |
| IL320459A (en) | 2022-10-27 | 2025-06-01 | Pfizer | Rna molecules encoding rsv-f and vaccines containing them |
| US20250367129A1 (en) | 2022-11-04 | 2025-12-04 | Pfizer Inc. | Lipid Compounds and Uses Thereof |
| EP4630057A1 (en) | 2022-12-08 | 2025-10-15 | Recode Therapeutics, Inc. | Lipid nanoparticle compositions and uses thereof |
| AU2023409158A1 (en) * | 2022-12-19 | 2025-07-03 | Fujifilm Corporation | Methods of delivering therapeutic agents, and lipid compositions |
| EP4658636A1 (en) | 2023-01-31 | 2025-12-10 | Pfizer Inc. | Lipid compounds and uses thereof |
| CN121263425A (zh) * | 2023-02-13 | 2026-01-02 | 旗舰创业创新第七有限责任公司 | 含可裂解接头的可电离脂质和用于治疗性组合物的脂质载体 |
| CN121487722A (zh) * | 2023-04-14 | 2026-02-06 | 北京剂泰生命科技有限公司 | 靶向脾的脂质纳米颗粒 |
| EP4704905A1 (en) * | 2023-05-02 | 2026-03-11 | Sage Therapeutics, LLC | Lymphatic system-targeting compounds |
| EP4704816A1 (en) * | 2023-05-03 | 2026-03-11 | ModernaTX, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| WO2025027492A1 (en) | 2023-07-31 | 2025-02-06 | Pfizer Inc. | Coronavirus antigen variants |
| WO2025034764A1 (en) * | 2023-08-07 | 2025-02-13 | Life Technologies Corporation | Lipids for delivery of nucleic acids to eukaryotic cells |
| US12364773B2 (en) | 2023-12-01 | 2025-07-22 | Recode Therapeutics, Inc. | Lipid nanoparticle compositions and uses thereof |
| WO2025126019A1 (en) | 2023-12-13 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025126113A1 (en) | 2023-12-15 | 2025-06-19 | Pfizer Inc. | Lipid compounds and uses thereof |
| WO2025126118A1 (en) | 2023-12-15 | 2025-06-19 | Pfizer Inc. | Lipid compounds and uses thereof |
| CN121015605A (zh) * | 2024-01-19 | 2025-11-28 | 晟迪生物医药(苏州)有限公司 | 含有可电离脂质的肺部递送系统、其制备方法和应用 |
| WO2025180480A1 (zh) * | 2024-03-01 | 2025-09-04 | 北京剂泰医药科技有限公司 | 靶向肌肉的脂质纳米颗粒 |
| WO2025186725A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Improved lnp formulations and uses thereof |
| WO2025207803A1 (en) * | 2024-03-26 | 2025-10-02 | General Therapeutics, Inc. | Lipid compounds, compositions and methods of use thereof |
| CN120718086A (zh) * | 2024-06-13 | 2025-09-30 | 仁景(苏州)生物科技有限公司 | 用于递送的脂质化合物和脂质纳米颗粒 |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2026029597A1 (ko) * | 2024-07-31 | 2026-02-05 | 주식회사 메디치바이오 | 신규한 스테롤 지질 또는 이의 유도체를 함유하는 지질 나노입자 조성물 |
| WO2026030275A1 (en) | 2024-08-01 | 2026-02-05 | Pfizer Inc. | Rna molecules |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
| US6071890A (en) * | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5840710A (en) * | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US5925628A (en) * | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
| US5942634A (en) * | 1997-05-09 | 1999-08-24 | Genzyme Corporation | Cationic amphiphiles for cell transfections |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| WO2007086881A2 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| CA2689042A1 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| EP2217221B1 (en) * | 2007-10-17 | 2018-06-27 | Korea Advanced Institute of Science and Technology | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
| WO2010021865A1 (en) | 2008-08-18 | 2010-02-25 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
| WO2010080724A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| WO2011000107A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| ES2579936T3 (es) | 2009-08-20 | 2016-08-17 | Sirna Therapeutics, Inc. | Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico |
| EP2485770A4 (en) | 2009-10-08 | 2013-04-10 | Merck Sharp & Dohme | Novel cationic lipids with short lipid chains for oligonucleotide delivery |
| EP3318248B1 (en) | 2009-12-01 | 2019-04-10 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| EP2525781A1 (en) | 2010-01-22 | 2012-11-28 | Schering Corporation | Novel cationic lipids for oligonucleotide delivery |
| WO2011143230A1 (en) | 2010-05-10 | 2011-11-17 | Alnylam Pharmaceuticals | Methods and compositions for delivery of active agents |
| US20130123338A1 (en) | 2010-05-12 | 2013-05-16 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
| US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
| DK2575767T3 (en) | 2010-06-04 | 2017-03-13 | Sirna Therapeutics Inc | HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES |
| US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| CA2809858C (en) | 2010-09-20 | 2019-11-12 | Sirna Therapeutics, Inc. | Novel low molecular weight cationic lipids for oligonucleotide delivery |
| CA2811430A1 (en) | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Low molecular weight cationic lipids for oligonucleotide delivery |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3485913A1 (en) | 2010-10-21 | 2019-05-22 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| WO2012061259A2 (en) | 2010-11-05 | 2012-05-10 | Merck Sharp & Dohme Corp. | Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| ES2795110T3 (es) | 2011-06-08 | 2020-11-20 | Translate Bio Inc | Lípidos escindibles |
| US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
| WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| WO2013086354A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| WO2013116126A1 (en) | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| EP2817287B1 (en) | 2012-02-24 | 2018-10-03 | Arbutus Biopharma Corporation | Trialkyl cationic lipids and methods of use thereof |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| KR20140048404A (ko) * | 2012-10-11 | 2014-04-24 | 포항공과대학교 산학협력단 | 저밀도 지단백질 유사 나노입자 및 이를 포함하는 간 표적 진단 및 치료용 조성물 |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| CN105143456A (zh) | 2013-03-15 | 2015-12-09 | 不列颠哥伦比亚大学 | 用于转染的脂质纳米粒子和相关方法 |
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| EP4186888B1 (en) * | 2017-03-15 | 2025-11-26 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| CA3055653A1 (en) * | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| US11529314B2 (en) * | 2017-11-10 | 2022-12-20 | Board Of Regents, The University Of Texas System | Lipid-based nanoparticles for encapsulation and sustained release of therapeutic agents |
| CN118697900A (zh) | 2019-01-31 | 2024-09-27 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
-
2021
- 2021-08-06 MA MA71659A patent/MA71659A/fr unknown
- 2021-08-06 CA CA3189854A patent/CA3189854A1/en active Pending
- 2021-08-06 AU AU2021320426A patent/AU2021320426A1/en not_active Abandoned
- 2021-08-06 US US18/040,485 patent/US20230285310A1/en active Pending
- 2021-08-06 KR KR1020237007762A patent/KR20230087443A/ko not_active Withdrawn
- 2021-08-06 CN CN202180068470.XA patent/CN116348147A/zh active Pending
- 2021-08-06 MX MX2023001461A patent/MX2023001461A/es unknown
- 2021-08-06 EP EP21762908.8A patent/EP4192433A2/en active Pending
- 2021-08-06 BR BR112023001955A patent/BR112023001955A2/pt not_active Application Discontinuation
- 2021-08-06 JP JP2023507600A patent/JP2023538260A/ja active Pending
- 2021-08-06 IL IL300111A patent/IL300111A/en unknown
- 2021-08-06 WO PCT/US2021/045038 patent/WO2022032154A2/en not_active Ceased
- 2021-08-06 TW TW110129202A patent/TW202214215A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022032154A2 (en) | 2022-02-10 |
| CN116348147A (zh) | 2023-06-27 |
| US20230285310A1 (en) | 2023-09-14 |
| IL300111A (en) | 2023-03-01 |
| JP2023538260A (ja) | 2023-09-07 |
| KR20230087443A (ko) | 2023-06-16 |
| AU2021320426A1 (en) | 2023-03-23 |
| EP4192433A2 (en) | 2023-06-14 |
| CA3189854A1 (en) | 2022-02-10 |
| TW202214215A (zh) | 2022-04-16 |
| WO2022032154A3 (en) | 2022-04-21 |
| BR112023001955A2 (pt) | 2023-04-11 |
| MA71659A (fr) | 2025-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001461A (es) | Composiciones para la administracion de moleculas de carga activa al epitelio de las vias respiratorias. | |
| CL2022002481A1 (es) | Compuestos antivirales y métodos para la administración de los mismos | |
| ES2741439T3 (es) | Compuestos aromáticos sustituidos | |
| MX369828B (es) | Sistemas para tratar infecciones pulmonares. | |
| BR112021006458A2 (pt) | composto de isoindolina, seu método de preparação, composição farmacêutica e uso | |
| BRPI0917549B8 (pt) | dispositivo para a liberação de um medicamento | |
| BR112015024869A2 (pt) | administração nasal | |
| WO2011082488A1 (en) | Bisphenol derivative therapeutics and methods for their use | |
| CR9504A (es) | Imidazoquinolinas como inhibidores de cinasa de lipido | |
| BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
| MXPA04011384A (es) | Uso de agentes de union del receptor edg en cancer. | |
| JP2011126918A (ja) | 神経系の障害の処置 | |
| MX2020003961A (es) | Uso de inhibidores de p38 para reducir la expresion de dux4. | |
| Ko et al. | Sphingosine-1-phosphate mediates fibrosis in orbital fibroblasts in Graves' orbitopathy | |
| BR112021018335A2 (pt) | Derivados de benzodiazepina como inibidores de rsv | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| BR112014008036A2 (pt) | tratamento de rinite | |
| JP2023516431A (ja) | ミトコンドリア機能の改善または機能障害の軽減のための治療 | |
| BR112015026053A2 (pt) | composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratamento de um paciente sofrendo ou susceptível a sofrer de um distúrbio respiratório e para fabricação de uma composição farmacêutica | |
| Kukharsky et al. | In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches | |
| CO2021000229A2 (es) | Compuestos de pirazol e imidazol para la inhibición de il-17 y rorgamma | |
| US20170035859A1 (en) | Methods and compositions for treating nephrogenic diabetes insipidus | |
| BR112021006488A2 (pt) | compostos e composições para o tratamento de condições associadas com atividade do receptor apj | |
| Wang et al. | Mitophagy in the pathogenesis and management of disease | |
| KR102407059B1 (ko) | 갑상선 베타-작용제의 사용 |